多发性骨髓瘤软组织浆细胞瘤专家综述:定义、评估与治疗
本综述定义了多发性骨髓瘤中两类软组织受累:仅软组织血行播散的髓外(EMD)和源自骨骼病灶的副骨骼(PS)浆细胞瘤。EMD常伴高危细胞遗传学、治疗耐药且预后较PS差。PS推荐蛋白酶体抑制剂方案后行ASCT;EMD不适合ASCT者用RVD,适合者用VTD-RVD/PACE后SCT。
要点
- EMD常伴高危细胞遗传学、治疗耐药,预后较PS差。
- PS用蛋白酶体抑制剂方案后ASCT;EMD不适合ASCT用RVD,适合者用VTD-RVD/PACE后SCT。
核心结论
- EMD疾病常与高危细胞遗传学、治疗耐药及较PS受累更差的预后相关。
- PS受累患者最佳选择可能是以蛋白酶体抑制剂为基础的方案,适合移植者后续行ASCT。
- 不适合ASCT的EMD患者最佳选择可能是以蛋白酶体抑制剂为基础的方案如RVD。
- 适合大剂量治疗的EMD患者应考虑骨髓瘤/淋巴瘤样方案如VTD-RVD/PACE后续行SCT。
- EMD和PS复发时已尝试多种策略,但仍为高度未满足需求人群。
研究设计与样本
- 本综述定义了多发性骨髓瘤中两类软组织受累:仅软组织血行播散的髓外(EMD)和源自骨骼病灶的副骨骼(PS)浆细胞瘤。
主要发现
- EMD疾病常与高危细胞遗传学、治疗耐药及较PS受累更差的预后相关。
关键数值与推荐
- PS受累患者可能最佳选择是以蛋白酶体抑制剂为基础的方案,适合移植者后续行ASCT。
- 不适合ASCT的EMD患者可能最佳选择是以蛋白酶体抑制剂为基础的方案如RVD。
- 适合大剂量治疗的EMD患者应考虑骨髓瘤/淋巴瘤样方案如VTD-RVD/PACE后续行SCT。
临床怎么用
- 根据软组织受累类型(EMD或PS)及移植资格选择治疗方案。
- PS用蛋白酶体抑制剂方案后ASCT;EMD不适合ASCT用RVD,适合者用VTD-RVD/PACE后SCT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this review, two types of soft-tissue involvement in multiple myeloma are defined: (i) extramedullary (EMD) with haematogenous spread involving only soft tissues and (ii) paraskeletal (PS) with tumour masses arising from skeletal lesions. The incidence of EMD and PS plasmacytomas at diagnosis ranges from 1·7% to 4·5% and 7% to 34·4% respectively. EMD disease is often associated with high-risk cytogenetics, resistance to therapy and worse prognosis than in PS involvement. In patients with PS involvement a proteasome inhibitor-based regimen may be the best option followed by autologous stem cell transplantation (ASCT) in transplant eligible patients. In patients with EMD disease who are not eligible for ASCT, a proteasome inhibitor-based regimen such as lenalidomide-bortezomib-dexamethasone (RVD) may be the best option, while for those eligible for high-dose therapy a myeloma/lymphoma-like regimen such as bortezomib, thalidomide and dexamethasone (VTD)-RVD/cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) followed by SCT should be considered. In both EMD and PS disease at relapse many strategies have been tried, but this remains a high-unmet need population.
引用
- Rosiñol L, Beksac M, Zamagni E, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021. PMID: 33724461. doi:10.1111/bjh.17338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。